Patents by Inventor Albert W. Garofalo

Albert W. Garofalo has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • INDAZOLES AND AZAINDAZOLES AS LRRK2 INHIBITORS
    Publication number: 20230148214
    Abstract: The present invention is directed to indazole and azaindazole compounds which are inhibitors of LRRK2 and are useful in the treatment of CNS disorders.
    Type: Application
    Filed: March 5, 2021
    Publication date: May 11, 2023
    Inventors: Albert W. Garofalo, Jacob Bradley Schwarz, Fabio Maria Sabbatini, Silvia Bernardi, Marco Migliore, Federica Budassi, Claudia Beato
  • INDAZOLES AND AZAINDAZOLES AS LRRK2 INHIBITORS
    Publication number: 20230077268
    Abstract: The present invention is directed to indazole and azaindazole compounds which are inhibitors of LRRK2 and are useful in the treatment of CNS disorders.
    Type: Application
    Filed: May 11, 2022
    Publication date: March 9, 2023
    Inventors: Albert W. Garofalo, Stéphane De Lombaert, Jacob Bradley Schwarz, Daniele Andreotti, Fabio Maria Sabbatini, Elena Serra, Silvia Bernardi, Marco Migliore, Federica Budassi, Claudia Beato
  • Indazoles and azaindazoles as LRRK2 inhibitors
    Patent number: 11427558
    Abstract: The present invention is directed to indazole and azaindazole compounds which are inhibitors of LRRK2 and are useful in the treatment of CNS disorders.
    Type: Grant
    Filed: July 10, 2020
    Date of Patent: August 30, 2022
    Assignee: ESCAPE Bio, Inc.
    Inventors: Albert W. Garofalo, Stéphane De Lombaert, Jacob Bradley Schwarz, Daniele Andreotti, Fabio Maria Sabbatini, Elena Serra, Silvia Bernardi, Marco Migliore, Federica Budassi, Claudia Beato
  • INDAZOLES AS LRRK2 INHIBITORS
    Publication number: 20220162192
    Abstract: The present invention is directed to indazole compounds which are inhibitors of LRRK2 and are useful in the treatment of CNS disorders.
    Type: Application
    Filed: March 20, 2020
    Publication date: May 26, 2022
    Inventors: Albert W. Garofalo, Stéphane De Lombaert, Daniele Andreotti, Fabio Maria Sabbatini, Elena Serra, Silvia Bernardi, Marco Migliore, Federica Budassi, Claudia Beato
  • Hydrazinyl-Pyrrolo Compounds and Methods for Producing a Conjugate
    Publication number: 20220153696
    Abstract: The present disclosure provides conjugate structures and hydrazinyl-pyrrolo compound structures used to produce these conjugates. The disclosure also encompasses methods of production of such conjugates, as well as methods of using the same.
    Type: Application
    Filed: October 8, 2021
    Publication date: May 19, 2022
    Inventors: David Rabuka, Aaron Edward Albers, Romas Alvydas Kudirka, Albert W. Garofalo
  • Anti-Her2 Antibody-Maytansine Conjugates and Methods of Use Thereof
    Publication number: 20220023440
    Abstract: The present disclosure provides anti-HER2 antibody-maytansine conjugate structures. The disclosure also encompasses methods of production of such conjugates, as well as methods of using the same.
    Type: Application
    Filed: July 22, 2021
    Publication date: January 27, 2022
    Inventors: David Rabuka, Aaron Edward Albers, Robyn M. Barfield, Gregory W. deHart, Penelope M. Drake, Romas Alvydas Kudirka, Albert W. Garofalo, Jesse M. McFarland
  • Hydrazinyl-pyrrolo compounds and methods for producing a conjugate
    Patent number: 11180451
    Abstract: The present disclosure provides conjugate structures and hydrazinyl-pyrrolo compound structures used to produce these conjugates. The disclosure also encompasses methods of production of such conjugates, as well as methods of using the same.
    Type: Grant
    Filed: December 20, 2019
    Date of Patent: November 23, 2021
    Assignee: Redwood Bioscience, Inc.
    Inventors: David Rabuka, Aaron Edward Albers, Romas Alvydas Kudirka, Albert W. Garofalo
  • FUSED TETRAZOLES AS LRRK2 INHIBITORS
    Publication number: 20210261553
    Abstract: The present invention is directed to fused tetrazoles of formula (IA) which are inhibitors of LRRK2 and are useful in the treatment of CNS disorders.
    Type: Application
    Filed: May 14, 2019
    Publication date: August 26, 2021
    Inventors: Albert W. Garofalo, Daniele Andreotti, Silvia Bernardi, Elena Serra, Marco Migliore, Fabio Maria Sabbatini, Claudia Beato, Paolo Vincetti, Federica Budassi
  • Anti-HER2 antibody-maytansine conjugates and methods of use thereof
    Patent number: 11097013
    Abstract: The present disclosure provides anti-HER2 antibody-maytansine conjugate structures. The disclosure also encompasses methods of production of such conjugates, as well as methods of using the same.
    Type: Grant
    Filed: September 26, 2018
    Date of Patent: August 24, 2021
    Assignee: Redwood Bioscience, Inc.
    Inventors: David Rabuka, Aaron Edward Albers, Robyn M. Barfield, Gregory W. deHart, Penelope M. Drake, Romas Alvydas Kudirka, Albert W. Garofalo, Jesse M. McFarland
  • PYRAZOLOPYRIMIDINE DERIVATIVES AND THE COMPOSITIONS AND METHODS OF TREATMENT REGARDING THE SAME
    Publication number: 20210163489
    Abstract: The present disclosure is directed to pyrazolo[1,5-a]pyrimidine compounds of formula (I), pharmaceutical compositions thereof and methods for modulating or activating a Parkin ligase The present disclosure is also directed to methods of treating and/or reducing the incidence of diseases or conditions related to the activation of Parkin ligase. R21, R22, R23, R24 and R25 are as defined herein.
    Type: Application
    Filed: February 2, 2021
    Publication date: June 3, 2021
    Inventors: Jennifer JOHNSTON, Albert W. GAROFALO, Paul Ross FATHEREE
  • PYRAZOLOPYRIMIDINE DERIVATIVES AND THE COMPOSITIONS AND METHODS OF TREATMENT REGARDING THE SAME
    Publication number: 20200317674
    Abstract: The present disclosure is directed to pyrazolo[1,5-a]pyrimidine compounds of formula (I), pharmaceutical compositions thereof and methods for modulating or activating a Parkin ligase The present disclosure is also directed to methods of treating and/or reducing the incidence of diseases or conditions related to the activation of Parkin ligase. R21, R22, R23, R24 and R25 are as defined herein.
    Type: Application
    Filed: June 5, 2017
    Publication date: October 8, 2020
    Applicants: An2H Discovery Limited, An2H Discovery Limited
    Inventors: Jennifer JOHNSTON, Albert W. GAROFALO, Paul Ross FATHEREE
  • Hydrazinyl-Pyrrolo Compounds and Methods for Producing a Conjugate
    Publication number: 20200317610
    Abstract: The present disclosure provides conjugate structures and hydrazinyl-pyrrolo compound structures used to produce these conjugates. The disclosure also encompasses methods of production of such conjugates, as well as methods of using the same.
    Type: Application
    Filed: December 20, 2019
    Publication date: October 8, 2020
    Inventors: David Rabuka, Aaron Edward Albers, Romas Alvydas Kudirka, Albert W. Garofalo
  • Hydrazinyl-pyrrolo compounds and methods for producing a conjugate
    Patent number: 10604483
    Abstract: The present disclosure provides conjugate structures and hydrazinyl-pyrrolo compound structures used to produce these conjugates. The disclosure also encompasses methods of production of such conjugates, as well as methods of using the same.
    Type: Grant
    Filed: June 7, 2019
    Date of Patent: March 31, 2020
    Assignee: Redwood Bioscience, Inc.
    Inventors: David Rabuka, Aaron Edward Albers, Romas Alvydas Kudirka, Albert W. Garofalo
  • HYDRAZINYL-PYRROLO COMPOUNDS AND METHODS FOR PRODUCING A CONJUGATE
    Publication number: 20190389800
    Abstract: The present disclosure provides conjugate structures and hydrazinyl-pyrrolo compound structures used to produce these conjugates. The disclosure also encompasses methods of production of such conjugates, as well as methods of using the same.
    Type: Application
    Filed: June 7, 2019
    Publication date: December 26, 2019
    Inventors: David Rabuka, Aaron Edward Albers, Romas Alvydas Kudirka, Albert W. Garofalo
  • TRIAZOLE BENZAMIDE DERIVATIVES AND THE COMPOSITIONS AND METHODS OF TREATMENT REGARDING THE SAME
    Publication number: 20190359578
    Abstract: The present disclosure is directed to triazole benzamide compounds of formula (I) and formula (II), pharmaceutical compositions thereof and methods for modulating or activating a Parkin ligase The present disclosure is also directed to methods of treating and/or reducing the incidence of diseases or conditions related to the activation of Parkin ligase. R1, R2, R3, M1, M2, M3, L1, L2, and L3 are as defined herein.
    Type: Application
    Filed: December 14, 2018
    Publication date: November 28, 2019
    Inventors: Jennifer JOHNSTON, Albert W. GAROFALO, Paul Ross FATHEREE
  • Hydrazinyl-pyrrolo compounds and methods for producing a conjugate
    Patent number: 10464894
    Abstract: The present disclosure provides conjugate structures and hydrazinyl-pyrrolo compound structures used to produce these conjugates. The disclosure also encompasses methods of production of such conjugates, as well as methods of using the same.
    Type: Grant
    Filed: September 26, 2016
    Date of Patent: November 5, 2019
    Assignee: Redwood Biosciences, Inc.
    Inventors: David Rabuka, Aaron Edward Albers, Romas Alvydas Kudirka, Albert W. Garofalo
  • Triazole benzamide derivatives and the compositions and methods of treatment regarding the same
    Patent number: 10308617
    Abstract: The present disclosure is directed to triazole benzamide compounds of formula (I) and formula (II), pharmaceutical compositions thereof and methods for modulating or activating a Parkin ligase The present disclosure is also directed to methods of treating and/or reducing the incidence of diseases or conditions related to the activation of Parkin ligase. R1, R2, R3, M1, M2, M3, L1, L2, and L3 are as defined herein.
    Type: Grant
    Filed: June 5, 2017
    Date of Patent: June 4, 2019
    Assignee: AN2H DISCOVERY LIMITED
    Inventors: Jennifer Johnston, Albert W. Garofalo, Paul Ross Fatheree
  • ANTI-HER2 ANTIBODY-MAYTANSINE CONJUGATES AND METHODS OF USE THEREOF
    Publication number: 20190111151
    Abstract: The present disclosure provides anti-HER2 antibody-maytansine conjugate structures. The disclosure also encompasses methods of production of such conjugates, as well as methods of using the same.
    Type: Application
    Filed: September 26, 2018
    Publication date: April 18, 2019
    Inventors: David Rabuka, Aaron Edward Albers, Robyn M. Barfield, Gregory W. deHart, Penelope M. Drake, Romas Alvydas Kudirka, Albert W. Garofalo, Jesse M. McFarland
  • Anti-HER2 antibody-maytansine conjugates and methods of use thereof
    Patent number: 10124070
    Abstract: The present disclosure provides anti-HER2 antibody-maytansine conjugate structures. The disclosure also encompasses methods of production of such conjugates, as well as methods of using the same.
    Type: Grant
    Filed: May 27, 2015
    Date of Patent: November 13, 2018
    Assignee: Redwood Bioscience, Inc.
    Inventors: David Rabuka, Aaron Edward Albers, Robyn M. Barfield, Gregory W. deHart, Penelope M. Drake, Romas Alvydas Kudirka, Albert W. Garofalo, Jesse M. McFarland
  • TRIAZOLE BENZAMIDE DERIVATIVES AND THE COMPOSITIONS AND METHODS OF TREATMENT REGARDING THE SAME
    Publication number: 20180118697
    Abstract: The present disclosure is directed to triazole benzamide compounds of formula (I) and formula (II), pharmaceutical compositions thereof and methods for modulating or activating a Parkin ligase The present disclosure is also directed to methods of treating and/or reducing the incidence of diseases or conditions related to the activation of Parkin ligase. R1, R2, R3, M1, M2, M3, L1, L2, and L3 are as defined herein.
    Type: Application
    Filed: June 5, 2017
    Publication date: May 3, 2018
    Inventors: Jennifer Johnston, Albert W. Garofalo